Intercept Pharmaceuticals (ICPT) PT Lowered to $115 at RBC Capital
Tweet
Share
E-mail
Get Alerts ICPT Hot Sheet
Price: $19.00 --0%
Rating Summary:
13 Buy, 17 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 53
Rating Summary:
13 Buy, 17 Hold, 3 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 11 | New: 53
Join SI Premium – FREE
RBC Capital lowered its price target on Intercept Pharmaceuticals (NASDAQ: ICPT) to $115.00 (from $116.00) while maintaining an Outperform rating.
Analyst Brian Abrahams notes Ocaliva PBC revenues slightly beat expectations, with strengthening U.S. and ex-U.S. uptake following the label update. He said this should set a solid foundation as investors continue to shift focus away from NT PBC performance and toward the 1H19 REGENERATE interim.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- PB Fintech Limited (POLICYBZ:IN) PT Lowered to INR1,425 at Investec
- Mirum Pharmaceuticals (MIRM) PT Raised to $144 at Citizens
- JPMorgan Starts Robotis Co Ltd (108490:KS) at Overweight
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS View, Analyst PT ChangeRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
